The data was murky, and the benefits were ambiguous at best.
In June 2021, the FDA approved aducanumab—the first Alzheimer's drug in nearly two decades to target the disease's underlying biology rather than its symptoms—through an accelerated pathway that bypassed the objections of its own advisory panel. The decision reflects a tension as old as medicine itself: the desperate hope of millions living with a devastating illness weighed against the scientific discipline that protects them from false promises. By conditioning approval on future proof of efficacy, the agency neither fully embraced nor rejected the drug, leaving patients, families, and physicians to navigate a threshold where urgency and uncertainty meet.
- For the first time since 2003, a drug targeting Alzheimer's root pathology—amyloid plaques—has been approved, raising hopes for millions who have had no disease-modifying options.
- The FDA's own advisory panel voted against approval, and independent scientists warn that clinical trial data is ambiguous, safety risks including brain hemorrhages are real, and annual costs between $20,000 and $50,000 are difficult to justify without proven benefit.
- Patient advocacy groups pushed hard for access, forcing regulators to balance scientific rigor against the moral weight of a disease that affects over 40 million people worldwide with no cure in sight.
- The FDA approved the drug conditionally, requiring Biogen to conduct post-market trials and reserving the right to withdraw it—a compromise that has satisfied neither critics nor supporters.
- Experts fear this approval could erode regulatory standards at a fragile moment for public trust in science, setting a precedent that may shape how future uncertain therapies reach desperate patients.
On a June morning in 2021, the FDA approved aducanumab—marketed as Aduhelm—for early-stage Alzheimer's disease, a decision that immediately divided the medical world. The approval came with a significant condition: manufacturer Biogen must conduct additional studies to prove the drug actually works. It was a compromise that satisfied almost no one.
Alzheimer's is a progressive disease that robs millions of their thinking and independence. More than 40 million people worldwide live with it, and in the United States it is the third leading cause of death among those over 65. For decades, available treatments addressed only symptoms—none could stop or reverse the disease itself. Aducanumab represented something different: it targets beta-amyloid plaques, the underlying pathology of Alzheimer's, making it the first disease-modifying therapy since 2003 if it proves effective.
The drug's path to approval was troubled from the start. Biogen initially halted two Phase 3 trials after concluding the drug had failed, then reexamined the data and found apparent benefit in one study among patients receiving high doses over extended periods. An FDA advisory panel voted against recommending approval in November 2020, arguing the evidence was unconvincing. Independent experts agreed. Yet the FDA approved it anyway through an accelerated pathway, citing consistent and dose-dependent reduction of amyloid plaques across all studies as a surrogate marker likely to predict clinical benefit.
Physician and researcher Jason Karlawish, who spent 18 years telling patients there was nothing new for Alzheimer's, was sharply critical. He said he would not recommend the drug to his patients, pointing to murky trial data, an annual cost of up to $50,000, and a documented risk of small brain hemorrhages—a risk heightened in carriers of the APOE4 gene associated with late-onset Alzheimer's. Families choosing to pursue treatment would face painful conversations about genetic risk and hereditary implications for their children.
Beyond individual patients, the approval stirred a wider concern: that lowering the evidentiary bar for a high-profile disease could set a dangerous precedent for future drug regulation. With projections suggesting Alzheimer's cases could exceed 100 million by 2050, the pressure to approve new treatments is immense—but so is the risk of offering false hope at great cost. The FDA's decision left the field in an unusual position: a drug that might help, might harm, and whose true effects remain genuinely unknown is now available to the people who need answers most.
On a June morning in 2021, the FDA made a decision that would ripple through neurology clinics and living rooms across America: it approved aducanumab, a drug designed to treat early-stage Alzheimer's disease. The approval came with a caveat—the agency required the manufacturer, Biogen, to conduct additional studies to prove the drug actually works. It was a compromise that satisfied almost no one.
Alzheimer's is a progressive neurological disease that steals thinking and independence from millions. More than 40 million people worldwide live with it. In the United States alone, it ranks as the third leading cause of death among people over 65, trailing only cancer and cardiovascular disease. The disease typically begins after age 60, though neurological changes can start years or decades before symptoms appear. For decades, the only treatments available addressed symptoms—they could slow decline temporarily, but none could stop or reverse the disease itself.
Aducanumab, marketed as Aduhelm, represented something different. Developed by Biogen in collaboration with Eisai, it targets beta-amyloid plaques in the brain—the underlying pathology of Alzheimer's rather than just its symptoms. If it worked, it would be the first disease-modifying therapy approved since 2003. The drug's path to approval was messy. Biogen initially halted two Phase 3 trials, announcing the drug had failed. Then the company reexamined the data and found that patients receiving high doses over extended periods showed benefit in one of the studies. On that basis, they requested FDA approval.
In November 2020, an FDA advisory panel voted by majority against recommending approval. The panelists argued the data did not convincingly demonstrate that aducanumab slowed cognitive decline. Three committee members later published a detailed critique of the evidence. Independent experts and scientists echoed the concern: the drug had not demonstrated sufficient benefit to outweigh its risks. Yet patient advocacy groups pushed hard for access, and the FDA ultimately approved it through an accelerated pathway—a mechanism designed for serious or potentially fatal diseases where a drug shows promise based on a surrogate marker likely to predict clinical benefit, even amid some uncertainty.
Patricia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, defended the decision. She noted that one of the two Phase 3 trials met its primary endpoint, showing reduced clinical decline. More importantly, across all studies, aducanumab consistently and convincingly reduced amyloid plaques in the brain in a dose- and time-dependent manner. The agency expected this reduction to translate into slowed cognitive deterioration. But the approval came with strings: Biogen must conduct a post-approval controlled trial to verify the drug actually improves memory and cognitive symptoms. If it doesn't work as intended, the FDA warned, the agency can remove it from the market.
Jason Karlawish, a physician and researcher at the University of Pennsylvania who has spent 18 years telling patients and families there is nothing new for Alzheimer's, was blunt in his criticism. He wrote that the few medications he prescribes offer only modest help with cognitive problems. He would not recommend aducanumab to his patients, he said, and he agreed with analyses showing the trial data was murky. The cost—between $20,000 and $50,000 per person annually—made the uncertain benefit harder to justify. Karlawish also flagged a serious safety concern: the drug carries a risk of small brain hemorrhages, a risk amplified in people carrying the APOE4 gene, which is associated with late-onset Alzheimer's. If families chose to treat a parent with aducanumab, they would be forced into difficult conversations about genetic risk and whether their own children might develop the disease.
The approval raised a broader worry among experts: that it might lower standards for future drug approvals at a moment when public trust in science was already fragile. More than 100 drugs have been studied for Alzheimer's since 1998, yet only five have been approved to help manage symptoms. As projections suggested the number of people with Alzheimer's could reach 65 million by 2030 and exceed 100 million by 2050, the pressure to approve new treatments was intense. But rushing a drug with unproven clinical benefit, some feared, could set a dangerous precedent. The FDA's decision to approve aducanumab while demanding proof it actually works left the field in an unusual position: patients and doctors would have access to a drug that might help, might harm, and whose true effects remain unknown.
Citações Notáveis
The few treatments I prescribe are only modestly effective for cognitive problems, and I would not recommend aducanumab to my patients. The data is murky, and the benefits are ambiguous at best.— Jason Karlawish, physician and Alzheimer's researcher, University of Pennsylvania
Aduhelm is the first treatment directed at the underlying pathology of Alzheimer's disease—the presence of beta-amyloid plaques in the brain. If the drug doesn't work as intended, we can take measures to remove it from the market.— Patrizia Cavazzoni, FDA Center for Drug Evaluation and Research
A Conversa do Hearth Outra perspectiva sobre a história
Why did the FDA approve a drug that its own advisory panel voted against?
Because the panel voted against it, but the FDA has the authority to override that recommendation. The agency used an accelerated pathway designed for serious diseases where there's some promise but uncertainty remains. Patient groups were pushing hard for access, and Biogen had data showing the drug reduced amyloid plaques in the brain—a biological marker associated with Alzheimer's. The FDA bet that reducing plaques would eventually reduce cognitive decline, even though it hadn't been proven yet.
But if the drug doesn't actually slow memory loss, what's the point of reducing plaques?
That's exactly what the skeptics asked. The drug targets the underlying disease mechanism rather than just symptoms, which is theoretically important. But there's a gap between theory and reality. One trial showed clinical benefit, one didn't. The data was contradictory enough that independent experts said it didn't justify approval. The FDA essentially said: we'll approve it, but you have to prove it works in a follow-up study, or we'll pull it.
What happens to patients in the meantime?
They face a difficult choice. The drug costs $20,000 to $50,000 a year. It carries a real risk of brain hemorrhages, especially for people with a certain genetic variant. And nobody knows if it will help their memory or cognition. Doctors like Karlawish say they won't recommend it because the evidence doesn't support spending that much money and taking that risk for an uncertain benefit.
Is there a chance the follow-up study proves the drug works?
There's a chance. The biological data is real—the drug does reduce amyloid plaques consistently. Whether that translates into meaningful cognitive improvement is what the next trial will test. But experts worry that approving it first and studying it later sets a precedent that could weaken standards for other drugs.
What does this mean for the millions of people with Alzheimer's right now?
For most, it probably means nothing changes. The drug is for early-stage disease, and it's expensive. But it does mean families will have to decide whether to try a treatment with unclear benefits and real risks. And it signals that the FDA is willing to approve drugs based on biological markers rather than proven clinical outcomes—which could be good or bad depending on how it's used going forward.